Abstract-Preeclampsia is a major cause of maternal and fetal mortality and morbidity worldwide. The differential expression of several microRNAs (miRNAs) has been found in preeclamptic placentas. However, great conflict exists regarding this aspect, and detailed examinations have largely been lacking of miRNA profiles in different parts of the placenta and in maternal plasma of women with this disorder. In this study, a total of 9 downregulated miRNAs (miR-195, miR-223, miR-218, miR-17, miR-18a, miR-19b1, miR-92a1, miR-379, and miR-411) and 7 upregulated miRNAs (miR-210, miR-30a-3p, miR-518b, miR-524, miR-17-3p, miR-151, and miR-193b) were identified in severe preeclampsia (sPE) placentas when compared with normal pregnant controls. In addition, sampling position in the chorionic or basal plate of placenta led to evident variations in differential miRNAs of sPE placentas. In a prospective pregnant cohort, we found that the circulating levels of 3 members of miR-17-92 cluster (ie, miR-18a, miR-19b1, and miR-92a1) were significantly lower, whereas that of miR-210 was higher in sPE patients than those in normal controls at gestational weeks 15 to 18 and at term. The results of in situ hybridization revealed the localization of miR-18a, miR-92a1, and miR-210 in various subtypes of placental trophoblasts and endothelial cells. In human trophoblast cell line, HTR8/SVneo cells, miR-18a could promote trophoblast cell invasion via targeting and suppressing Smad2 expression. This study provides fundamental evidences for exploring the roles of miRNAs in the pathogenesis of preeclampsia. 
P reeclampsia affects ≈2% to 7% pregnancies worldwide and is a major disorder that leads to maternal, fetal, and neonatal mortality and morbidity. 1 Placental defects, especially the dysregulation of trophoblast cell behaviors, have been assumed to substantially mediate the clinical disease. 2, 3 Identifying the genes that are specifically dysregulated in preeclamptic placentas may be a useful manner for exploring the biomarkers and the cause of preeclampsia.
MicroRNAs (miRNAs) are a class of 20-to 22-nt, endogenous, noncoding RNAs. 4 These small molecules play roles in a diverse range of cell events. 5, 6 Interestingly, the human placenta is an organ rich in miRNA expression, and a great number of differentially expressed miRNAs have been found in preeclamptic placentas. [7] [8] [9] [10] [11] [12] [13] [14] Some of these differential miRNAs are demonstrated to participate in the regulation of trophoblast cell invasion, 15 placental immune activation, and platelet aggregation. 16, 17 However, the relevant investigations have been far less sufficient.
A notable fact is that there exists a great conflict in describing miRNA profiles in preeclamptic placenta. Such inconsistencies might be because of the differences in sample sizes or in experimental settings and platforms. However, the location in placenta from where the samples were taken may have more influence. The human placenta is not a homogenous tissue, and different parts of the placenta are composed of various cell types. The expression profiles and functions of miRNAs in these cell types may vary significantly. Accordingly, detailed investigations on these issues are of great value in elucidating the roles of small RNAs during physiological and pathological pregnancies.
In this study, we attempted to identify differential miRNAs in severe preeclampsia (sPE) placentas derived from Chinese Han pregnant women. The expression patterns of differential miRNAs in the chorionic and basal plates of placental tissues were separately measured. Members of miR-17-92 cluster were subjected to further investigation, including their localization in placentas, their differences in maternal plasma between sPE and normal pregnancy, as well as the modulation of trophoblast cell invasion by miR-18a. This study gives a detailed demonstration on miRNA expression patterns in preeclamptic placenta and demonstrates the invasion modulating effect of miR-18a. The data provide important evidences for exploring the pathogenesis of the disease from a noncoding RNA viewpoint.
Materials and Methods
All the details of the materials and methods are provided in the online-only Data Supplement.
Study Subjects
In this study, the collection of human placenta tissues and plasma specimens was performed with the permission of the local ethical committee in the Institute of Zoology, Chinese Academy of Sciences, and informed consent was obtained from all patients enrolled in this study.
Placentas and maternal blood samples from normal pregnant and preeclamptic women were obtained from pregnant women who underwent perinatal care in Peking University Third Hospital from August 2010 to October 2012. Totally 20 severe preeclamptic patients who delivered at 35th to 39th weeks and 33 normal pregnant women who delivered at 37th to 39th weeks were enrolled in this study. Their placentas at deliveries and plasma samples at gestational weeks 15 to 18 and weeks 35 to 38 were used. The clinical characteristics of these women are summarized in Table 1 .
miRNA Microarray Analysis
Large-scale profiling of miRNA expression was achieved by mammalian miRNA chip array (V2.0, Capitalbio, Beijing, China), which stems from the miRbase release 8.2 (Wellcome Trust Genome Campus, Cambridge, United Kingdom; ftp://mirbase.org/pub/mirbase/8.2/). 18 The data were analyzed using Significance Analysis of Microarrays software (http://www-stat.stanford.edu/_tibs.SAM).
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RT-qPCR
SYBR Premix Ex Taq assays (Takara, Dalian, China), MiRcute miRNA qPCR assays (Tiangen, Beijing, China), and TaqMan Gene Expression Assays (Life Technologies, CA) were separately performed for the quantitative analysis of mRNA and miRNA expression in human placenta and plasma.
In Situ Hybridization for miRNAs
Frozen sections were subjected to in situ hybridization using antisense 3ʹ-digoxygenin-labeled miRCURY LNA miRNA Detection probes (Exiqon, Copenhagen, Denmark).
Cell Culture and Transient Transfection
HTR8/SVneo cells were cultured in RPMI 1640 culture medium (Life technologies) supplemented with 10% fetal bovine serum.
Transient transfection of siRNA or miRNA duplexes or plasmids was performed using Lipofectamine 2000 reagent (Life technologies).
Transwell Invasion Assay
Transwell insert invasion assay was conducted in 24-well fitted inserts (8 μm pore size; Millipore Corp, MA). Cell invasion index was presented as a percentage of invaded cell number compared with the corresponding control.
Western Blotting
Protein levels of Smad2 in cells or placental tissues were measured by Western blotting with specific antibodies (Cell Signaling Technology, MA).
Luciferase Assays
Luciferase assays were performed using a reporter plasmid carrying the wild type (WT) or mutated 3ʹ-UTR of human Smad2 gene.
Statistical Analysis
All statistical analyses were performed with Statistical Package for the Social Sciences software (version 17.0; SPSS Inc, Chicago, IL). Multiple comparisons were performed using R software (version 3.0.2; http://www.r-project.org/), and the differences are considered significant when q<0.05. Comparisons between 2 groups were estimated using independent samples t test, and P<0.05 was considered statistically significant. 
Results
Screening of Differential miRNAs in sPE Placenta by miRNA Microarray
A comprehensive miRNA microarray analysis was performed using RNAs extracted from random sites of 3 sPE placentas and 3 normal placentas. Of the 184 human miRNAs detected by the microarray, 11 and 16 miRNAs were, respectively, found to be down-and upregulated by at least 1.5-fold in sPE placentas, compared with normal placentas (P<0.05). These 27 miRNAs were chosen as candidates of differential miRNAs in sPE placentas (Table 2) .
Expression Patterns of Differential miRNAs in Preeclampsia Placenta
RT-qPCR was performed to validate the differential expression of the chosen 27 miRNAs in sPE placentas. Placenta specimens were derived from 14 sPE patients and 33 normal pregnant women, and the chorionic and basal plates of each specimen were separately analyzed. According to expression patterns, the miRNAs were classified into 3 groups, as described below. The first group included 13 miRNAs, the differential expression of which in sPE placentas, as revealed by genechip, was fully validated by RT-qPCR. As shown in Figure 1A to 1D, 6 miRNAs (miR-195, miR-223, miR-218, miR-18a, miR-379, and miR-411) were significantly downregulated, and 7 miRNAs (miR-210, miR-30a-3p, miR-518b, miR-524, miR-17-3p, miR-151, and miR-193b) were significantly upregulated in sPE placentas, compared with normal pregnant controls. These data were in agreement with genechip results. One interesting observation was that these miRNAs exhibited different patterns between the chorionic plate and basal plate of the placenta. Specifically, miR-223, miR-218, and miR-411 were downregulated in both chorionic and basal plates of sPE placentas, whereas downregulation of miR-195, miR-18a, and miR-379 only occurred in chorionic plates, but not in basal plates, of sPE placentas. Upregulated expression was found in basal plates of sPE placentas for miR-210, miR-30a-3p, miR-518b, miR-524, miR-17-3p, miR-151, and miR-193b.
The second group included 12 miRNAs (miR-181a, miR-638, miR-515-3p, miR-525-3p, miR-19a, miR-542-3p, miR-584, miR-362, miR-31, miR-363, miR-590, and miR-296). Inconsistent with genechip results, their expression in sPE placentas did not evidently differ from those in normal controls, as revealed by qPCR. In addition, their patterns were not different between the chorionic and basal plates of placentas ( Figure 1E and 1F) .
For the other 2 miRNAs (miR-519e-5p and miR-214), qPCR results were in opposite to those of the genechip ( Figure 1G and 1H ).
Expression Patterns of miR-17-92 Cluster Members in sPE Placentas
The miR-17-92 cluster encodes 6 unique mature miRNA sequences: miR-17, miR-18a, miR-19a, miR-19b1, miR-20a, and miR-92a1. According to the results of miRNA microarray, 5 of 6 members in miR-17-92 cluster (miR-17, miR-18a, miR19a, miR-19b, and miR-20a) were downregulated in sPE placenta. We, therefore, expanded the validation study to include all of the 6 members in the placentas. As shown in Figure 2A and 2B, miR-17, miR-18a, miR-19b1, and miR-92a1 were significantly downregulated in chorionic plates, but not in basal plates, of sPE placentas, compared with the corresponding controls. The expression of miR-19a and miR-20a exhibited no significant differences between sPE and control, in either chorionic or basal plate. 
Differences in miR-17-92 Cluster Members in the Plasma Between sPE Patients and Normal Controls
We further measured the levels of miR-17, miR-18a, miR-19b1, and miR-92a1 as well as miR-210 in plasma derived from sPE patients and normal pregnant women at weeks 15 to 18 and weeks 35 to 39. In agreement with our expectations, TaqMan qPCR data demonstrated that the circulating levels of miR-18a, miR-19b1, and miR-92a1 were significantly lower, and that of miR-210 was clearly higher in sPE plasma at both gestational stages, when compared with the corresponding normal controls ( Figure 2C and 2D) . Plasma miR-17 did not vary between sPE and control groups at the 2 gestational stages.
Localization of miR-18a, miR-92a1, and miR-210 in Human Normal Placentas
The localization of miR-18a, miR-19b1, miR-92a1, and miR-210 in human placenta was examined using specific in situ hybridization. The probe for miR-19b1 did not work, and the results for the other 3 miRNAs are shown in Figure 3 . The localization patterns for miR-18a, miR-92a1, and miR-210 were similar in normal placental tissues derived from the first trimester (weeks 7-8) and from full term. These small RNAs were predominantly produced by various subtypes of trophoblasts, including villous cytotrophoblast cells, syncytiotrophoblasts, column cytotrophoblast cells ( Figure 3A, 3D , and 3G), and interstitial trophoblast cells invading the decidual stroma ( Figure 3C , 3F, and 3I) that were identified by CK-7 immunostaining in adjacent sections ( Figure 3L ). In term placenta, staining for these miRNAs was also found in villous core capillary endothelial cells ( Figure 3B, 3E, and 3H) . No positive signals were found in decidual stromal cells ( Figure 3C , 3F, and 3I).
Validation of Smad2 as the Direct Target of miR18a in Human Trophoblast Cells
Target gene prediction using TargetScan software (http://www. targetscan.org/) 20 indicated Smad2 as one of the targets of miR18a. We performed target validation study in human trophoblastic cell line HTR8/SVneo. As shown in Figure 4A to 4C, the transfection of miR-18a mimics in cells resulted in the downregulation of Smad2 expression at both mRNA and protein levels to 73% and 60% of scramble controls, respectively. According to bioinformatics analysis, the seed sequence of miR-18a was complementary to the 136 to 142 nt of 3ʹUTR in Smad2 mRNA. The luciferase reporter construct (WT-UTR) carrying a 300-bp DNA fragment of 3ʹUTR in human Smad2 mRNA or the point-mutated report construct (MUT-UTR) was transfected into HTR8/SVneo cells together with miR-18a mimics and renilla luciferase vector (pRL-TK). Forty-eight hours after transfection, miR-18a mimics could evidently reduce the relative luciferase activity of WT-UTR construct by ≈56% compared with scramble control, but could not affect the relative luciferase activity of MUT-UTR construct ( Figures 4D-4F ). The data strongly proved Smad2 as the target gene of miR-18a in human trophoblast cells.
MiR-18a Could Regulate Trophoblast Cell Invasion via Targeting Smad2
To demonstrate whether miR-18a can influence trophoblast cell behaviors via targeting Smad2, we performed transwell insert invasion assay in HTR8/SVneo cells. As shown in Figure 5 and Figure S1A and S1B in the online-only Data Supplement, the overexpression of miR-18a in HTR8/SVneo cells significantly promoted cell invasiveness to ≈1.8-fold of control cells. The overexpression of Smad2-expressing construct (pcDNA4-Smad2) could reduce basal cell invasiveness by 30% and completely block the invasion-promoting effect caused by miR-18a in HTR8/SVneo cells ( Figure 5 ). These data demonstrated that Smad2 was directly involved in invasion regulation by miR-18a in human trophoblast cells. 
Inverse Correlation Between the Expression Levels of miR-18a and Smad2 Protein in Severe Preeclamptic Placentas
We then examined the expression pattern of Smad2 in sPE placenta. Data of qPCR revealed that the mRNA expression of Smad2 had no obvious difference in sPE and normal placentas, in either chorionic or basal plates ( Figure 6A and 6B) . However, Western blotting results demonstrated that Smad2 protein levels in the chorionic plate of sPE placentas were ≈1.6-fold of the corresponding normal control, whereas that in the basal plates did not differ ( Figure 6C and 6D) . The differential pattern of Smad2 in sPE placenta exhibited inverse correlation to that of miR-18a expression as shown in Figure 2A and 2B.
Discussion
It has been well recognized that any single molecule or signaling pathway can hardly be responsible for the occurrence of the complex syndrome, preeclampsia. miRNAs have been indicated to be finetuned factors in maintaining homoeostasis in many organs, including the placenta, by targeting a large number of genes and participating in various cellular events. The identification of dysregulated miRNAs in preeclamptic placentas and the clarification of gene networks that are regulated by those miRNAs are, therefore, likely to be novel steps in understanding the pathogenesis of such compromised pregnancies.
In the present study, we started from examining the differences in miRNA expression between preeclampsia and control placentas. Thirteen differential miRNAs were identified in sPE placenta. Some of our data are consistent with other reports, such as the downregulation of miR-18a, miR-195, miR-223, and miR-411, 8, 11 and the upregulation of miR-30a-3p, miR-193b, miR-210, and miR-518b in preeclamptic placentas. [7] [8] [9] [10] [11] [12] 21, 22 Meanwhile, for the first time to our knowledge, several miRNAs (miR-17, miR-17-3p, miR-19b1, miR-92a1, miR-379, miR-524, miR-151 , miR-218) were found to be aberrantly expressed in sPE placentas.
To date, several studies have shown aberrant miRNA profiles in preeclamptic placentas, using various platforms and techniques. [7] [8] [9] [10] [11] [12] [13] [14] 21, 23 Among these studies, there have been some conflicting results. We proposed that the position from which the samples were taken from the placenta is a crucial issue to consider. This notion has been well accepted in terms of mRNA expression, but has not been demonstrated in miRNA respect. In this study, several miRNAs exhibited distinct expression in either chorionic or basal plates of sPE placentas. These results indicate that different sampling methods could result in varying, or even opposite, results in miRNA expression analyses. This has been further supported by different expression patterns of several known differential miRNAs [7] [8] [9] [10] [11] 13, 14, 23 in different parts of sPE placenta, which may partly explain the controversial reports regarding their differences between preeclamptic placentas and Figure S2) . Whereas, the spatially specific expression profiles of miRNAs in human placenta may help to speculate about the pathophysiological roles of these small RNAs in the occurrence of preeclampsia.
One important question to be addressed is whether these differential placental miRNAs contribute to the pathological change of preeclampsia or they are just the consequence of the disorder at late gestation. For the pregnancy-associated disease of preeclampsia, there are challenges in addressing the discrepancy between the key pathophysiological changes that are initiated well before 20 weeks gestation and the clinical symptoms that are not manifest until after 20 weeks gestation. 24 Circulating miRNAs in pregnant women are suggested to be mainly coming from the placenta. 25, 26 The prospective plasma samples at early gestation are, therefore, valuable species for exploring potentially pathological factors of the disorder. Our observations on the circulating levels of several miRNAs in sPE patients at 15th to 19th weeks of gestation strongly indicated their possibly aberrant expression in sPE placenta at the first half gestation and their participation in the early pathological events of sPE.
The next step is to clarify the contribution of differential miRNAs to the defects in early placental development. It has been proposed that members in the same miRNA cluster might have similar functions. 27 In the present study, we chose miR-17-92 cluster to perform the functional study in human trophoblast cells. The miR-17-92 cluster has been reported to be frequently amplified in malignancies and solid tumors, 28 and its oncogenic activity has been well demonstrated. 29 Considering the many similarities in proliferative and invasive properties between placental trophoblast cells and cancer cells, and our finding that several members in this cluster are largely located in various subtypes of trophoblast cells, we propose that these small RNAs may participate in the regulation of some principal trophoblast cell events. The downregulation of 4 members in this cluster, that is, miR-17, miR-18a, miR-19b1 and miR-92a1, in severe preeclamptic placenta further suggests their involvement in modulating trophoblast cell activities. Our results revealed that miR-18a could modulate trophoblast cell invasion via repressing Smad2 expression. Bioinformatic analysis also reveals that miR-17 and miR-19b1 can potentially modulate TGF-β signaling, with Smad6/Smad7 and Smad4/Smad5 as the predicted targets, respectively. These targets are central mediators of TGF-β signaling, which plays an essential role in regulating many trophoblast cell activities. [30] [31] [32] It is most likely that the miR-17-92 cluster may regulate placenta development via, at least in part, finetuning TGF-β signaling. A pathway enrichment analysis for the predictive targets of miR-17-92 cluster using the DAVID Gene Functional Classification Tool (version 6.7; http://david.abcc.ncifcrf.gov/home.jsp) 33, 34 also reveals the potential involvement of this cluster in modulating several signaling pathways being essential to placental development, such as gonadotropin-releasing hormone signaling, p53 pathway, Wnt signaling, extracellular matrix-receptor interaction, etc ( Figure S3 ). Further in-depth functional study is necessary to eventually discover the working mechanisms of these small molecules that account for the occurrence of preeclampsia.
Another interesting finding in this study is the differences in plasma miRNAs between preeclampsia patients and normal controls. Plasma miRNAs have been reported to be not affected by incubation temperature or pH or even by RNase A treatment. 35, 36 The stable properties, as well as the early differential patterns of plasma miRNAs in preeclampsia patients, as shown in our study and other reports, 25, 37 strongly suggest the significant potential of using these molecules in the noninvasive prenatal diagnosis of preeclampsia. However, their low abundance in circulation 26 and the specificity and sensitivity in measuring circulating miRNAs hamper the identification of plasma miRNA biomarkers for diseases of pregnancy.
Perspectives
Further in vitro and in vivo studies using specific miRNAdeficient cells/animals are warranted to comprehensively understand the roles of the aberrantly expressed miRNAs in the onset or progression of preeclampsia. Meanwhile, it would be of great clinical interest to further test these small RNAs as potential biomarkers for sPE in a larger and prospective cohort.
What Is New?
• The unique expression patterns of 16 microRNAs (miRNAs) in the chorionic and basal plates of severe preeclamptic placentas are demonstrated, strongly supporting the notion that the sampling position in the placenta should be considered when identifying differential miRNAs with regard to this disorder.
• The differences of miR-18a, miR-19b1, miR-92a1, and miR-210 in severe preeclamptic plasma at early to mid-gestation indicated their participation in the early pathological events of severe preeclampsia (sPE).
• miR-18a could promote trophoblast cell invasion via targeting and suppressing Smad2 expression.
What Is Relevant?
• Preeclampsia is a serious hypertensive disorder in pregnancy, which is a major cause of maternal and fetal mortality and morbidity worldwide.
Identifying the miRNAs that are specifically dysregulated in preeclamptic placentas and maternal plasma has been demonstrated to be a useful manner for exploring the biomarkers and cause of the disease. Moreover, identifying the targets of miRNAs and demonstrating the relevance of miRNAs and their functional targets in preeclamptic placenta would be of great value in elucidating the molecular mechanisms that are likely involved in the pathogenesis of preeclampsia.
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